Table 3.
NTM species and antibiotic susceptibilities as determined by broth microdilution
|
NTM spp. |
n |
Number and proportion (%) of susceptible strains to given antibiotics |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| AK | CIP | CLA | DOX | IPM | LZD | MOX | SXT | ||
|
M. fortiutum |
6 |
6 |
4 |
- |
1 |
1 |
5 |
4 |
3 |
|
M. cheloane-abscessus |
6 |
6 |
4 |
6 |
1 |
3 |
5 |
6 |
4 |
| Unidentified RGM |
8 |
8 |
1 |
8 |
3 |
0 |
8 |
5 |
2 |
|
Total RGM |
20 |
20 (100) |
9 (45) |
14 (100) |
5 (25) |
4 (20) |
18 (90) |
15 (75) |
9 (45) |
| MAC |
6 |
- |
- |
6 |
- |
- |
4 |
1 |
- |
|
M. kansasii |
4 |
- |
1 |
4 |
- |
- |
3 |
4 |
2 |
| Unidentified SGM |
7 |
- |
- |
7 |
- |
- |
3 |
6 |
- |
| Total SGM | 17 | - | - | 17 (100) | - | - | 10 (58.8) | 11 (64.7) | - |
Lines labeled with Total RGM and Total SGM represent total number of RGM or SGM tested for each antibiotic listed.
NTM, non-tuberculous mycobacteria; MAC, Mycobacterium avium complex; n = number of isolates tested; AK, amikacin; CIP, ciprofloxacin; CLA, clarithromycin; DOX, doxycycline; IPM, imipenem; LZD, linezolid; MOX, moxifloxacin; SXT, cotrimoxazole.